How to Get Wegovy for Weight Loss: Eligibility, Prior Authorization, and Common Denials
Key Takeaways
- FDA-Approved Eligibility: Wegovy is approved for adults with a BMI ?30, or a BMI ?27 with a weight-related comorbidity. It is also approved for adolescents (12+) with a BMI in the 95th percentile or higher.
- Prior Authorization is Standard: Most insurance plans require a prior authorization (PA) to cover Wegovy, which involves your doctor submitting detailed clinical documentation.
- Common Denial Reasons: Denials often occur due to not meeting BMI criteria, step therapy failures, or plan exclusions for weight loss medications.
- Appeal Process is Key: A denial is not the final word. A structured appeal process, including a Letter of Medical Necessity, can often lead to approval.
- Cardiovascular Indication: In March 2024, Wegovy was also approved to reduce cardiovascular risk, which may open new coverage pathways.
Quick Answer
Getting Wegovy for weight loss legally requires a prescription from a licensed healthcare provider. To be eligible, you must meet specific FDA criteria: a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition like hypertension or type 2 diabetes. Most insurance plans will not cover the medication without a prior authorization (PA), a process where your doctor must justify the medical necessity of the prescription. If your PA is denied, common reasons include not meeting the clinical criteria, your insurance plan excluding weight loss drugs, or failing to complete required "step therapy." A formal appeal can often overturn a denial.
Who This Is For (and Who Should Not Use It)
Wegovy is specifically designed for individuals struggling with chronic weight management. The FDA has approved its use for:
- Adults with an initial Body Mass Index (BMI) of 30 kg/m? or greater (obesity).
- Adults with an initial BMI of 27 kg/m? or greater (overweight) who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1].
- Adolescents aged 12 years and older with an initial BMI at the 95th percentile or greater for their age and sex (obesity) [1].
In March 2024, the FDA expanded Wegovy's indication to include reducing the risk of major adverse cardiovascular events (like heart attack and stroke) in adults with established cardiovascular disease and either overweight or obesity [2].
Who Should Not Use Wegovy
Wegovy is not safe for everyone. It is contraindicated (should not be used) in patients with:
- A personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- A known serious hypersensitivity to semaglutide or any of its ingredients [1].
Due to a boxed warning for the risk of thyroid C-cell tumors, it is crucial to discuss your personal and family medical history with your doctor.
The Step-by-Step Process to Get Wegovy
Navigating the path to obtaining Wegovy involves several key steps, from initial consultation to handling insurance hurdles.
Step 1: Consultation with a Healthcare Provider
Your journey begins with an appointment with a healthcare provider (e.g., primary care physician, endocrinologist). During this visit, your provider will:
- Assess Your Eligibility: They will calculate your BMI and review your medical history for weight-related comorbidities to see if you meet the FDA-approved criteria.
- Discuss Your Health History: This includes a thorough review of your personal and family history to rule out contraindications, such as MTC or MEN 2.
- Evaluate Previous Weight Loss Attempts: Be prepared to discuss your past efforts with diet, exercise, and any other weight loss medications you have tried.
- Set Realistic Expectations: Your provider will discuss the potential benefits, side effects, and the importance of combining Wegovy with diet and exercise.
If you are a suitable candidate, your provider will write you a prescription.
The Prior Authorization (PA) Process
Simply having a prescription is rarely enough to get Wegovy covered by insurance. Most plans require a prior authorization. This is a process where your doctor's office must submit a formal request to your insurance company, providing clinical documentation to prove that the medication is medically necessary for you.
What Your Doctor Will Submit:
- Your current BMI and weight
- A list of your weight-related comorbidities (e.g., hypertension, dyslipidemia)
- Documentation of your participation in a comprehensive weight management program (diet and exercise)
- A history of other weight loss medications you have tried and failed (if required by your plan for "step therapy")
This process can take several days to a few weeks. Your pharmacy will usually notify you once the PA has been approved or denied [3].
Handling a Prior Authorization Denial
It is common for initial PA requests for Wegovy to be denied. Do not be discouraged. Your insurance company is required to provide a specific reason for the denial. The most common reasons include:
| Denial Reason | Explanation | How to Address It |
|---|---|---|
| Not Meeting Clinical Criteria | Your BMI or comorbidity status does not match the insurer's requirements. | Double-check the submitted data for accuracy. If correct, this is a difficult denial to overturn. |
| Plan Exclusion | Your insurance plan explicitly does not cover anti-obesity medications. | Check if the cardiovascular risk reduction indication is covered. You may need to appeal to your employer's benefits manager. |
| Step Therapy Failure | You have not tried and failed one or more of the insurer's preferred (and cheaper) alternative medications. | Your doctor can provide a clinical rationale for why the preferred alternatives are not appropriate for you. |
| Missing Information | The PA form was incomplete or lacked sufficient detail. | Your doctor's office can resubmit the form with the required information. |
The Appeal Process
If your PA is denied, you have the right to appeal the decision. This is a formal process that often yields results.
- Understand the Reason: Review the denial letter carefully to understand exactly why it was rejected.
- Gather Evidence: Work with your doctor to gather additional supporting documentation.
- Submit a Letter of Appeal: Your doctor will typically write a Letter of Medical Necessity, a detailed letter explaining why Wegovy is the most appropriate treatment for you, citing clinical evidence and your specific health status.
- Request a Peer-to-Peer Review: If the written appeal is denied, your doctor can request a "peer-to-peer" review, which is a direct phone call with a medical director at the insurance company to discuss your case [4].
Download: Prior Authorization Appeal Checklist
Stay organized during the appeal process. Download our free checklist to ensure you and your doctor have all the necessary documentation.
Download PDF ChecklistFrequently Asked Questions (FAQ)
No. Wegovy is a prescription-only medication. Any service offering Wegovy without a consultation and prescription from a licensed healthcare provider is operating illegally and should be avoided.
Generally, no. Federal law prohibits Medicare Part D plans from covering drugs used for weight loss. However, coverage may be available if it is prescribed for its cardiovascular risk reduction indication, though this is still evolving [5].
Both are brand names for semaglutide, but they are approved for different uses and have different maximum doses. Ozempic is FDA-approved for type 2 diabetes, with a maximum dose of 2 mg. Wegovy is FDA-approved for chronic weight management, with a maximum dose of 2.4 mg.
Be wary of websites that offer Wegovy without a prescription, at unusually low prices, or ship from outside the U.S. Always look for pharmacies that require a valid prescription and are licensed in your state.
If your appeals are exhausted, you can consider paying the cash price (which is high, often over $1,300 per month) or using the Novo Nordisk savings card, which can reduce the cost if you have commercial insurance that covers Wegovy. You can also discuss alternative, more affordable weight loss medications with your doctor.
If approved, a PA is typically valid for 6 to 12 months. Your insurance plan will require your doctor to submit a reauthorization request at the end of that period, often requiring proof that you have lost a certain percentage of body weight to continue coverage.
References
- WEGOVY® (semaglutide) Prescribing Information. Novo Nordisk Inc.
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration.
- Initiating a Wegovy® PA. NovoMedLink.
- Wegovy® Exceptions, Denials, and Appeals Guide. Novo Nordisk.
- Medicare Part D Drug Formulary Coverage for Weight Loss Drugs. GoodRx.
Ready to Take the Next Step?
Download our free checklist to prepare for your conversation with your healthcare provider about whether a GLP-1 medication is right for you.